Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 –– FREEDOM2 trial open in South Korea, Australia, and New Zealand –– Well-funded with ...

Late in 2025, we covered the development of an AI system called Evo that was trained on massive numbers of bacterial genomes. So many that, when prompted with sequences from a cluster of related genes ...

Australia's Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small ...

Using personal and archival images, Tshepiso Moropa splices delicate collages that consider the ever-evolving nature of the stories we tell.

Concerns are rising after reports that some high school athletes are allegedly using various AI tools to enhance game film in hopes of attracting college recruiters ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...

Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint ...

Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the ...

Dr. McBain studies policies and technologies that serve vulnerable populations. On any given night, countless teenagers confide in artificial intelligence chatbots — sharing their loneliness, anxiety ...

The head of the sample platform thinks creatives “deserve better” than AI tools that do all the work for them. The head of the sample platform thinks creatives “deserve better” than AI tools that do ...